

February 16, 2026

JCR Pharmaceuticals Co., Ltd.

### JCR Organizes and Conducts API Plant Tour for Individual Shareholders

**Hyogo, Japan – February 16, 2026** -- [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced it hosted an API (active pharmaceutical ingredient) plant tour for individual shareholders at its Kobe Science Park Center (KSPC) in Nishi-ku, Kobe City on February 13. The purpose of the tour was to deepen shareholders’ understanding of JCR’s business and manufacturing operations.

KSPC houses JCR’s API plant, completed in November 2022, and serves as a core manufacturing hub for the company. Approximately 30 individual shareholders took part in the event, selected from a large pool of applicants.

During the program, JCR briefed the stakeholders on the company’s focus on rare diseases and its biopharmaceutical manufacturing processes, followed by a tour of the plant. JCR provided an overview of the new formulation plant under construction at the site, which broke ground in February 2025; additionally, participants joined a networking session with JCR representatives.



New Formulation Plant (under construction)  
adjacent to the API facility



Networking session

Guided by its corporate philosophy — “We create treatments that go beyond rare disease to solve the world’s most complex healthcare challenges” — JCR will continue strengthening its R&D and manufacturing capabilities and keeping shareholders up-to-date on important developments and communications.

For more information on the completion of the KSPC API plant, visit:

<https://ssl4.eir-parts.net/doc/4552/tdnet/2200173/00.pdf>.

For more information on construction of the new formulation plant, visit:

<https://ssl4.eir-parts.net/doc/4552/tdnet/2572939/00.pdf>.

#### About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. We continue to build upon our 50-year legacy in Japan while expanding our global footprint into the U.S., Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases

including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. Our core values – Putting people first, Forging our own path, Always advancing, and Committed to excellence – mean that the work we do benefits all our stakeholders, including partners, patients and employees. We strive to expand the possibilities for patients while accelerating medical advancement at a global level. For more information, please visit JCR's global website: <https://jcrpharm.com/>.

**Contact:**

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###